Bluejay Therapeutics, a drug developer focused on serious viral and liver diseases, is considering a US initial public offering, according to people familiar with the matter.
The company could list as soon as next month, the people said, asking not to be identified because the information is confidential. Bluejay is working with JPMorgan Chase & Co., Jefferies Financial Group Inc. and Cantor Fitzgerald on the potential IPO, which could raise at least $150 million, they said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.